LokivetmabDose, contraindications and adverse effects for Dogs.

Caninized monoclonal antibody that neutralizes interleukin-31, the key itch-signaling cytokine in canine atopic dermatitis. Lokivetmab is indicated for the treatment of pruritus associated with allergic and atopic dermatitis in dogs of any age. Lokivetmab provides dose-related relief of pruritus within 24 to 72 hours that lasts for 4 to 8 weeks.

Lokivetmab is a caninized monoclonal antibody that neutralizes interleukin-31 (IL-31). IL-31 is produced by cutaneous activated T helper cells in dogs with atopic dermatitis; it binds to receptors in the spinal cord that then send signals to the brain to stimulate peripheral nerves to cause pruritus.

Lokivetmab is approved for use in dogs only and should not be used in any other species. The US label lists no contraindications, precautions, or warnings; however, in other countries, lokivetmab is labeled as contraindicated in dogs hypersensitive to it. When giving lokivetmab concurrently with vaccinations, administer at separate injection sites.

In the primary field safety study, pruritus as an adverse effect was reported less frequently in the lokivetmab-treated group versus pla- cebo14; otitis and dermatitis occurred at a similar frequency between treatment groups and may be attributed to lokivetmab’s mechanism of action (ie, reduces pruritus but does not affect inflammation related to allergic and atopic dermatitis).

■ Efficacy manifests as lessening of pruritus ■ Regular monitoring of treated dogs is recommended. ■ Any adverse effects suspected to be associated with lokivetmab should be reported to the manufacturer and the USDA.